Abstract IA08: Reprogramming human cancer cells in CDK4/6 inhibitor therapy

This study represents the first investigation of genes that discriminate sensitivity from resistance in targeting CDK4/CDK6 in human cancer, through integrative longitudinal analysis of whole exome and whole transcriptome sequencing in concert with protein expression analysis and functional studies. Selective inhibition of CDK4 induces pG1 in all MCL patients, which apparently reprograms MCL for clinical response to bortezomib through PI3K inactivation and suppression of genes for redox homeostasis.Citation Format: Selina Chen-Kiang, Maurizio Di Liberto, Priyanka Vijay, David Chiron, Xiangao Huang, Scott Ely, Olivier Elemento, Christopher Mason, Lewis Cantley, John P. Leonard, Peter Martin. Reprogramming human cancer cells in CDK4/6 inhibitor therapy. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr IA08.

Source: Molecular Cancer Research - November 9, 2016 Category: Cancer & Oncology Authors: Chen-Kiang, S., Liberto, M. D., Vijay, P., Chiron, D., Huang, X., Ely, S., Elemento, O., Mason, C., Cantley, L., Leonard, J. P., Martin, P. Tags: Targeting CDK/cyclins: Hormone Dependent Cancers and Beyond: Oral Presentations - Invited Abstracts Source Type: research